ALX Oncology Holdings Inc. (ALXO)

Market Cap	94.34M +9.7%
Revenue (ttm)	n/a
Net Income	-108.01M
EPS	-2.01
Shares Out	54.22M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,238,343
Open	1.825
Previous Close	1.570
Day's Range	1.630 - 1.930
52-Week Range	0.404 - 2.270
Beta	0.52
Analysts	Strong Buy
Price Target	3.30 (+89.66%)
Earnings Date	Mar 5, 2026

About ALXO

ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company’s lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squam...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jul 17, 2020
• Employees: 44
• Stock Exchange: NASDAQ
• Ticker Symbol: ALXO
• Website: https://www.alxoncology.com

Analyst Summary

According to 5 analysts, the average rating for ALXO stock is "Strong Buy." The 12-month stock price target is $3.3, which is an increase of 89.66% from the latest price.

Price Target

$3.3

(89.66% upside)

Analyst Consensus: Strong Buy